Arecor and Genzyme Form Collaboration to Advance Protein Therapeutics

CAMBRIDGE, England, April 13, 2010 - Genzyme Corporation and Arecor Limited today signed an agreement
providing for extensive collaboration on developing advanced formulations for
protein therapeutics. The agreement provides for a close working relationship
between Genzyme and Arecor in developing stable, high strength formulations
of labile biomolecules. This agreement is the result of a two year working
relationship where Arecor has demonstrated their technologies offer an
improvement over conventional approaches in protein formulation.

Dr. Robert Mattaliano, Group Vice President of Therapeutic Protein R&D
commented: "The Arecor technology has a demonstrated potential to
significantly improve the stability of complex biologicals by using novel
formulation design principles. Genzyme is pleased to establish this strategic
partnership in support of our goal to provide stable and convenient dosage
forms to patients and their caregivers."

Tom Saylor, CEO of Arecor said: "Formulation of the next generation of
biologics represents unique challenges to developers. Arecor has developed a
strong partnership with Genzyme and is privileged to work closely with one of
the world leaders in biotechnology to help enable new protein-based
therapeutics."

Arecor Limited was established to provide formulation solutions to
pharmaceutical and biotech companies developing drugs, vaccines, medical
devices and diagnostics. Proteins and vaccines are often fragile entities,
and stability can represent significant constraints in the development of new
products and extending the use of existing products. Arecor has developed
Arestat(TM), a patented set of tools for stabilization, to enable the
presentation of labile biologicals as stable aqueous formulations even at
high concentrations or in situations where cold storage is not practical or
desirable. Arestat(TM) can also protect proteins from degradation in the
presence of ionizing radiation typically used in the sterilization of medical
devices. As a simple reformulation, Arestat(TM) can be readily incorporated
into standard manufacturing practice, without covalent medication of the
biological and using excipients approved for the route of delivery. Arecor
currently has active feasibility programs and licenses with many of the top
pharmaceutical and biotech companies on a wide range of proteins and
vaccines.

    Contact: Tom Saylor
    Phone: +44-1223-426060
    Email: t.saylor@arecor.com

Contact: Tom Saylor, Phone: +44-1223-426060, Email: t.saylor at arecor.com